Thyroid cancer is the most common endocrine malignancy. Most thyroid cancer types
respond well to conventional treatment consisting of surgery and radioactive iodine (RAI) …

Precision medicine has ushered in a new era of targeted treatments for numerous
malignancies, leading to improvements in overall survival. Unlike traditional chemotherapy …

SciELO - Brasil - Diretriz Brasileira de Cardio-oncologia – 2020 Diretriz Brasileira de Cardio-oncologia
– 2020 Acessibilidade / Reportar erro Brasil Lista alfabética de periódicos Lista temática de …

Cardiovascular disease and cancer are 2 of the leading causes of death worldwide.
Although improvements in outcomes have been noted for both disease entities, the success …

This paper reviews current treatments for renal cell carcinoma/cancer (RCC) with the
multikinase inhibitors (MKIs) sorafenib, sunitinib, lenvatinib and axitinib. Furthermore, it …

Background Many oral anti-cancer drugs have come onto the market in the past 20 years.
For example, kinase inhibitors, such as the BCR-ABL and BRAF inhibitors, have markedly …

Aim In recent decades, there has been a revolutionary decrease in cancer-related mortality
and an increase in survival due to the introduction of novel targeted drugs. Nevertheless …

Diretriz Brasileira de Cardio-oncologia–2020 O relatório abaixo lista as declarações de
interesse conforme relatadas à SBC pelos especialistas durante o período de …

Introduction Nonalcoholic fatty liver disease (NAFLD) is replacing viral hepatitis as the
leading cause of chronic liver disease and hepatocellular carcinoma (HCC) in many …

Objective The SELECT trial showed progression-free survival (PFS) benefit for lenvatinib for
advanced radioiodine-refractory differentiated thyroid cancer (RAI-refractory or RR-DTC) …